Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

New data at ATS add to the body of evidence for Roche's Esbriet (pirfenidone) in idiopathic pulmonar

worldpharmanewsMay 27, 2017

Tag: Roche , IPF

PharmaSources Customer Service